Introduction
Transforming growth factor beta 1 (TGF-3 1)1 is a member ofa recently discovered family of homologous factors that are involved in a large variety of cell functions, ranging from cell growth and differentiation to extracellular matrix production and degradation (1, 2) . TGF-#l is produced by many cell types and most cells have high affinity receptors for TGF-# 1. One of the major storage sites for TGF-# I and the related molecule TGF-,32 is the bone matrix (3). TGF-,B2 is also found in platelets, the human prostatic adenocarcinoma cell line, PC-3, and human glioblastoma cells (4, 6) . Amino acid sequence analyses indicate that TGF-431 and TGF-32 differ from each other by forming growth factor beta. 32 amino acid substitutions, and have > 70% sequence identity (5) . Recent studies indicate that there may be separate receptors for TGF-,B1 and TGF-f#2 (7) . Whether there are functional differences between these receptors is unknown.
Evidence that TGF-,B may be involved in the bone resorption process has come from studies on neonatal mouse calvarial cultures in which TGF-fl1 stimulated bone resorption through an indirect mechanism by stimulating the production of PGE2 (8) . Prostaglandin production has been shown to be the main mechanism for the bone-resorbing effects of many cytokines in neonatal mouse calvariae (9, 11) . These other cytokines also stimulate bone resorption in cultures offetal rat long bones, a widely used alternative model for the study of bone resorption in vitro. Prostaglandin-dependent stimulation, however, could not account for the stimulatory effect of many factors such as epidermal growth factor, tumor necrosis factor, or TGF alpha, indicating different mechanisms for bone resorption in the two culture systems (12, 14) .
In this report, we show that the homologous growth regulatory peptides TGF-, I and TGF-(#2 inhibit bone resorption in fetal rat long bones and that their inhibitory effects on bone resorption in this system may be due to inhibition ofosteoclast precursor proliferation.
Methods
Reagents. TGF-Il and TGF-j32 were purified from bovine demineralized bone as previously described (3, 15 Culture technique. Fetal rat long bone cultures and neonatal mouse calvariae cultures were performed as described earlier (16, 17) . Bones were labeled with 45Ca by injecting the mothers 1 d before removal of the fetuses (long bones) or 1-2 d before delivery (calvariae). Long bones (radius and ulna) were dissected from 19-d-old fetal rats with removal of cartilage and fibrous tissue. Bones were cultured in 0.5 ml of serum-free Biggers-Gwatkin-Judah (BGJ) medium (Sigma Chemical Co.) supplemented with 1 mg/ml RIA-grade BSA (Sigma Chemical Co.). Bones were incubated on steel grids at the interphase between medium and a 95% air, 5% CO2 atmosphere at 37°C. Calvaria halves (frontal and parietal bones) were dissected from 4-d-old neonatal mice and cultured in 1 ml of serum-free BGJ medium containing 1 mg/ml BSA under the same conditions as described for the long bone cultures. All bones were precultured in medium for 24 h to remove exchangeable 41Ca. Bones were then cultured for 3 d (day 1-3) in fresh medium and after a second medium change the incubation was continued for another 3 d (day 4-6). TGF-#,B, TGF-#2, indomethacin, and HU were added during the medium changes at days 1 and 4. IL 
Results
We first examined the effects of TGF-j31 and TGF-(32 on bone resorption in the neonatal mouse calvariae system. Both factors increased bone resorption, but the increases were modest (Fig. 1, Table I ). Small but significant increases could be achieved with 1 ng/ml TGF-f#2 and 1-2 ng/ml TGF-# 1 ( Fig.   1 ). In some experiments, TGF-,B2 caused significant increases in bone resorption at concentrations of0.5 ng/ml. Increases in bone resorption with TGF-i 1 and TGF-,B2 could be completely inhibited by the prostaglandin synthesis inhibitor, indomethacin, during the first 3 d of incubation, indicating that these factors stimulated bone resorption via a prostaglandindependent mechanism, as has been shown before (9) . However, in repeated experiments, indomethacin only partially inhibited TGF-#3I-and TGF-,32-induced bone resorption during the second half ofthe 6-d incubation period (Table I) , suggesting that there may be another mechanism besides prostaglandin generation during this period.
We then determined if TGF-13I and TGF-,B2 would also increase bone resorption in the fetal rat long bone system. TGF-# I and TGF-,32 in concentrations up to 100 ng/ml, however, failed to increase bone resorption (Tables II and III) . On the contrary, overall analysis from eight independent experiments using 50 ng/ml TGF-j31 showed a significant decrease in bone resorption up to 30% during the second half of the 6-d incubation period (P < 0.01). TGF-,32 at 50 ng/ml significantly inhibited bone resorption in some experiments but failed to inhibit or rather slightly increased resorption in other experiments, and the overall analysis from five experiments at a concentration of 50 ng/ml revealed no significant difference from control bone resorption. Addition of indomethacin to TGF-f01-or TGF-,32-treated long bones was without additional effect (Table III) . We then determined if the inhibitory effect of TGF-,3l would be more pronounced in bones treated with bone-resorbing agents. Indeed, up to twofold increases in bone resorption caused by IL 1 and 1,25(OH)2D3 could be partially or even completely inhibited by TGF-$tl during the second half ofthe incubation period, and a similar inhibition was observed with TGF-,B2 (Fig. 2) . No significant decrease of bone resorp- tion could be observed when TGF-f3I or TGF-f32 was added to PTH-treated cultures (data not shown). HU is also ineffective against PTH-stimulated bone resorption in this system (18) . As in the calvarial system, TGF-42 seemed to be more potent than TGF-,Bl, since it decreased IL 1-mediated bone resorption at concentrations at which TGF-fl still failed to show inhibitory effects (Table IV) In most experiments, the effects of TGF-#3I and TGF-132
were much more pronounced during the second halfofthe 6-d incubation period. TGF-fll is known to inhibit cell proliferation in many cell lines (22) (23) (24) (25) (26) (27) and we therefore wondered whether the effects of TGF-3 in the long bone system might be due to a decrease in osteoclast precursor proliferation, which would explain the observed delayed decrease in bone resorption. We therefore compared the effects of TGF-,BI on long bone resorption with those of HU, a known inhibitor of DNA synthesis (28 A difference in proliferative capacity of osteoclast precursors might contribute to the observed difference of the effects of TGF-f3 in long bones and in calvariae. We therefore tested the effect of HU in the mouse calvariae system. Compared with the long bone system, HU had no effect on baseline or stimulated resorption (Table VII) at a concentration at which DNA synthesis was > 90% inhibited (Table VIII) . Since HU might lead to cell death, which could cause prostaglandin release and obscure inhibitory effects, HU was also tested in the presence of indomethacin. However, HU still had no effect on bone resorption (data not shown). Discussion TGF-,3l stimulated bone resorption in neonatal mouse calvariae cultures in concentrations as low as 1-2 ng/ml. In comparison, it did not stimulate bone resorption in fetal rat long Both culture methods are well established and are the most commonly used techniques for studying bone resorption in vitro. Most factors that stimulate bone resorption or inhibit bone resorption in one organ culture system have similar overall etects on bone resorption in the other system. It has, however, become obvious over recent years that the mechanisms for stimulation or inhibition of resorption in both systems can be at least partially different. This is particularly so for many growth factors that stimulate bone resorption in calvariae by increased prostaglandin production, but do not or only partially depend on prostaglaridin production for stimulation of bone resorption in fetal rat long bone (9) (10) (11) (12) (13) (14) (15) . Howevef, TGF-j31 and TGF-32 are as yet the only factors that seem actually to induce opposite effects on bone resorption in the two systems.
TGF-# l is a potent inhibitor of proliferation in most nonmesenchymal cell lines (22) (23) (24) (25) (26) (27) and recent studies have shown that TGF-j31 also inhibits the formation ofosteoclast-like multinucleated cells in long term bone marrow cultures (29), which is consistent with the data reported here. The decreases in bone resorption observed with TGF-3 in fetal rat long bones may therefore be caused by an inhibition of osteoclast precursor proliferation. A comparison between TGF-# 1 and the DNA synthesis inhibitor HU, which effectively inhibits osteoclast proliferation in long bones (18, 30) , showed that the inhibitory effects of TGF-#3l and HU in long bones were indeed similar in many aspects. Unlike calcitonin, which rapidly inhibits bone resorption by acting on mature osteoclasts (31), HU and TGF-#3l had little effect on bone resorption during the first half of the 6-d incubation period, but both inhibited bone resorption during the second half. HU and TGF-f31 were both able to inhibit mild increases in bone resorption induced by low concentrations of IL I but had little or no inhibitory effects at submaximal or maximal stimulatory concentrations or IL 1. Both agents were more effective when the bones were only pulsed with IL 1 from day 1 to day 3 instead of being exposed to IL generally less pronounced than that of HU, but it is possible that there might be additional effects of HU or TGF-0. Addition of indomethacin had no further effect on bone resorption in long bones treated with up to 50 ng/ml TGF-ft1 and TGF-,32, which makes prostaglandin-mediated effects at the concentrations of TGF-fl we used unlikely. It cannot be excluded, however, that higher concentrations of TGF-# I might also induce prostaglandin production in long bones.
In further contrast to fetal rat long bones, addition of HU at concentrations that nearly completely inhibited DNA synthesis had no effect on basal or stimulated bone resorption in calvariae in the presence and absence of indomethacin. Proliferation of osteoclast precursors, therefore, does not seem to contribute to the rate of bone resorption in calvariae.
Like TGF-3lB, TGF-fl2 stimulated bone resorption in calvariae and inhibited IL 1-and 1,25(OH)2D3-mediated increases in bone resorption in long boies. TGF-(32, however, was consistently more potent in calvariae and seemed to be also more potent in inhibiting IL 1-stimulated resorption in long bones. TGF-f#l and TGF-32 seem to bind preferentially to different subclasses of TGF-ll receptors, which might explain the differences in potency (8) ; l3oth are present in the bone environment and may work together to regulate TGF-fllike effects on bone more precisely.
Most of the TGF-fB produced by bone cells and present in bone cultures is part of a biologically inactive, high molecular weight complex and needs to be dissociated to gain activity (32) . Bone-resorbing agents such as PTH, IL 1, and 1,25(0H)2D3 have been shown to increase TGF-,3 activity in bone cultures during bone resorption (17) , which may be due to activation of TGF-i3 in the osteoclastic environment. TGF-f31 has been shown to stimulate proliferation and activity of osteoblastic cells in vitro (33-36) and active TGF-fl generated during osteoclastic resorption may function as a local coupling factor and stimulate new bone formation. TGF-fl may also complete the ongoing bone resorption process by a prostaglandin-mediated stimulation of resorption by mature osteoclasts and a simultaneous suppression of the recruitment of new osteoclasts. The differences we observed in TGF-,B effects on bone resorption in fetal rat long bones and neonatal mouse calvariae may be due to differences in cell populations and the developmental stage of each culture system. However, these differences may also simply reflect differences in species or bone structure. The further characterization of these systems will therefore be important in clarifying the role of TGF-,B on bone resorption.
